Northwest Biotherapeutics (NW Bio) has announced the commencement of a Phase III trial with DCVax-L for brain cancer at King’s College Hospital in the UK.
DCVax-L mobilises a cancer patient’s whole immune system to attack the full set of biomarker targets on the tumour, said the company.
In the previous two trials with patients treated with DCVax-L the tumours typically did not recur for two years, and patients typically lived for three years.
King’s College Hospital neuro-oncology lead and consultant neurosurgeon Dr. Keyoumars Ashkan said there is a great need for new and better treatments for brain cancers, which are some of the most lethal cancers.
"The positive data from the clinical trials in the US were very encouraging in delaying disease progression and extending survival times, without significant toxic side effects," Ashkan added.
"We are hopeful that similar results will be seen in the large, randomised clinical trial which we have now launched in the UK."
Three other sites in the UK are also preparing to open the trial, and nearly 20 sites in Germany are at different stages of preparation.
Some medical centres in other European countries have also requested to be added to the trial, said NW Bio.
This Phase III trial is currently underway in the US and is expected to enrol an aggregate total of 312 patients in the US and Europe.
NW Bio CEO Linda Powers noted that the trial is one of the first late-stage clinical trials with active immune therapies in Europe, and said that it is bringing patients a much needed new treatment option.
"We are excited to be launching this trial with King’s College Hospital, one of Europe’s premier opinion-leader institutions."